Knobloch Visiting Professor featuring Jose Pulido, MD, MS, MPH, MBA
Dr. Pulido is a board certified ophthalmologist with an extensive research portfolio that has focused on vitreoretinal infectious and inflammatory diseases, retinal degeneration, stem cells, checkpoint inhibitors, and immunotherapies. He has published close to 350 peer-reviewed ophthalmic papers, and numerous books, book chapters, and editorials. Dr. Pulido assumes his new role at Wills Eye Hospital as the Director of the Henry and Corrine Bower Memorial Laboratories for Translational Medicine in the Vickie and Jack Farber Vision Research Center at Wills Eye after fifteen years as Professor of Ophthalmology at Mayo Clinic.
Dr. Pulido earned his bachelor’s and master’s degrees in chemistry at the University of Chicago and a degree in medicine from Tulane University School of Medicine. He completed his ophthalmology residency and served as Chief Resident at the University of Illinois at Chicago. Following residency, he completed a vitreoretinal surgery and retina research fellowship at Bascom Palmer Eye Institute at the University of Miami School of Medicine. Before joining the Mayo Clinic, Dr. Pulido earned his MBA at the University of Iowa, completed an ocular oncology fellowship at Wills Eye Hospital and earned an MPH at the University of Illinois at Chicago. Dr. Pulido has held Visiting Professorships and has presented named lectures throughout the world. He holds more than a dozen patents, and has won many awards and high honors in the field of ophthalmology.
Dr. Pulido’s research interests focus on translating basic science to the clinical arena and much of his work has centered on vitreoretinal infectious and inflammatory diseases. In more recent work, Dr. Pulido has combined his interests in inflammatory diseases and oncology and developed a phase 1 trial using a VSV based vaccine for the treatment of metastatic uveal melanoma. At Wills Eye Hospital, Dr. Pulido will continue to pursue his passion for translational research of inflammatory diseases and immunotherapies to develop innovative clinical therapies for ocular diseases.